Xuxi Zhang

necessary, in the general diabetes clinic by the same physicians in charge of the group sessions) VA CSDM, 1996 Baseline: IG: 75 CG: 78 Follow ‐ up (2 years): IG: 63 CG: 67 Male patients with type 2 diabetes Female (%): 0 Mean age: 60.4±0.7 Duration of diabetes: 8.0±0.4 HbA1c (%):9.3±0.2 Blood pressure (mm Hg): Systolic: 136.1±1.8 Diastolic: 80.8±1.0 Total Cholesterol (mmol/l): LDL:  ‐  HDL:  ‐  BMI:  ‐  Without diabetic retinopathy (%): 38.7 Male patients with type 2 diabetes Female (%): 0 Mean age: 59.9±0.8 Duration of diabetes: 7.7±0.5 HbA1c (%): 9.5±0.2 Blood pressure (mm Hg): Systolic: 134.5±1.7 Diastolic: 80.9±0.9 Total Cholesterol (mmol/l): LDL:  ‐  HDL:  ‐  BMI:  ‐  Without diabetic retinopathy (%): 37.2 Randomized prospective trial USA Glycemic ‐ control intervention Intensive control group (the goal of intensive therapy was to obtain an HbAlc within two standard deviations of the mean of nondiabetic subjects (4.0 ‐ 6.1%).) vs. Standard control group (The goal of standard therapy was good general medical care and well ‐ being and avoiding excessive hyperglycemia, glycosuria, ketonuria, or hypoglycemia.) * In ACCORD Eye Study, 3472 participants were eligible for follow ‐ up at baseline and 2856 (82.5%) had both baseline and follow ‐ up data. Baseline data of 2856 patients were provided. # A total of 1263 ACCORD Eye study participants were also enrolled in the ACCORD Blood Pressure Study. † In this study, there were 55 participants in each cohort respectively and 102 remained in the study after six years with 51 in each cohort. Baseline data of 102 patients were provided. ‡ There were 40 patients enrolled in this study, 22 in intervention group and 18 in control group. Only 35 patients continued the one year follow ‐ up. Baseline data of 35 patients were provided. $ After the ACCORD trial was completed, surviving participants who were invited for follow ‐ up in the main study and who had fundus photographs at baseline were invited to have additional photographs 8 years after randomization. The effects of a mean of 3.7 years of intensive glycemic control and 5 years of intensive blood pressure control and/or fenofibrate on the progression of diabetic retinopathy during 8 years of follow ‐ up in the ACCORD Follow ‐ On (ACCORDION) Eye Study are reported here. & Reported here are the data from 858 of 1,791 subjects in the VADT who completed 7 ‐ fielstereo fundus photographs at baseline and 5 years later. The individuals included in this study were largely representative of the VADT cohort as a whole @ The results of the ADVANCE Retinal Measurements (AdRem) study, a substudy of ADVANCE. In addition to the inclusion and exclusion criteria of ADVANCE, patients were excluded from AdRem if they had had a previous ophthalmological intervention procedure (such as laser coagulation treatment or vitrectomy) or if it was unlikely that good quality stereo photographs could be taken, because of severe cataract or pupils that did not dilate to at least 4 mm. 7 189 Prevention and control of diabetic retinopathy